INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35 | +66.7% | 1,892 | 0.0% | 0.00% | – |
| Q2 2023 | $21 | -16.0% | 1,892 | 0.0% | 0.00% | – |
| Q1 2023 | $25 | +4.2% | 1,892 | 0.0% | 0.00% | – |
| Q4 2022 | $24 | -100.0% | 1,892 | -54.4% | 0.00% | – |
| Q3 2022 | $58,000 | +427.3% | 4,148 | +438.7% | 0.00% | – |
| Q2 2022 | $11,000 | -64.5% | 770 | -56.4% | 0.00% | – |
| Q1 2022 | $31,000 | +6.9% | 1,767 | 0.0% | 0.00% | – |
| Q4 2021 | $29,000 | +11.5% | 1,767 | 0.0% | 0.00% | – |
| Q3 2021 | $26,000 | -25.7% | 1,767 | 0.0% | 0.00% | – |
| Q2 2021 | $35,000 | -12.5% | 1,767 | 0.0% | 0.00% | – |
| Q1 2021 | $40,000 | -9.1% | 1,767 | 0.0% | 0.00% | – |
| Q4 2020 | $44,000 | -39.7% | 1,767 | 0.0% | 0.00% | – |
| Q3 2020 | $73,000 | -13.1% | 1,767 | 0.0% | 0.00% | – |
| Q2 2020 | $84,000 | -25.0% | 1,767 | 0.0% | 0.00% | – |
| Q1 2020 | $112,000 | -48.4% | 1,767 | 0.0% | 0.00% | – |
| Q4 2019 | $217,000 | +141.1% | 1,767 | +30.7% | 0.00% | – |
| Q3 2019 | $90,000 | -55.7% | 1,352 | -47.0% | 0.00% | – |
| Q2 2019 | $203,000 | -31.9% | 2,549 | -4.6% | 0.00% | -100.0% |
| Q1 2019 | $298,000 | +14.6% | 2,671 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $260,000 | +3.2% | 2,671 | +34.3% | 0.00% | 0.0% |
| Q3 2018 | $252,000 | +50.9% | 1,989 | 0.0% | 0.00% | – |
| Q2 2018 | $167,000 | +35.8% | 1,989 | 0.0% | 0.00% | – |
| Q1 2018 | $123,000 | +6.0% | 1,989 | 0.0% | 0.00% | – |
| Q4 2017 | $116,000 | +1.8% | 1,989 | 0.0% | 0.00% | – |
| Q3 2017 | $114,000 | -52.7% | 1,989 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $241,000 | +7.1% | 1,989 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $225,000 | +3.7% | 1,989 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $217,000 | -66.8% | 1,989 | -50.0% | 0.00% | 0.0% |
| Q3 2016 | $654,000 | +131.1% | 3,978 | +100.0% | 0.00% | 0.0% |
| Q2 2016 | $283,000 | +11.0% | 1,989 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $255,000 | +15.9% | 1,989 | +35.2% | 0.00% | 0.0% |
| Q4 2015 | $220,000 | -9.8% | 1,471 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $244,000 | -31.1% | 1,471 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $354,000 | +18.0% | 1,471 | +37.7% | 0.00% | 0.0% |
| Q1 2015 | $300,000 | +80.7% | 1,068 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $166,000 | -34.6% | 1,068 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $254,000 | +45.1% | 1,068 | +43.7% | 0.00% | 0.0% |
| Q2 2014 | $175,000 | – | 743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |